Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: A multi-center, naturalistic study

Journal of Psychiatric Research

Volumn 49, Issue 1, 2014, Pages 75-82

  Han, Changsu ^a   Wang, Sheng Min ^b   Seo, Ho Jun ^b   Lee, Boung Chul ^c   Jeon, Hong Jin ^d   Kim, Won ^e   Kwak, Kyung Phil ^f   Pae, Chi Un ^b,g  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Hallym University   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Inje University   (South Korea)

^f Dongguk University College of Medicine   (South Korea)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Augmentation; Combination; Depression; Switching

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SERTRALINE; TIANEPTINE; VENLAFAXINE;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MIDDLE AGED; MULTICENTER STUDY; NECK PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RESTLESSNESS; TREATMENT RESPONSE; TREMOR; URINE INCONTINENCE; WEIGHT CHANGE; XEROSTOMIA; YOUNG ADULT;

AUGMENTATION; COMBINATION; DEPRESSION; SWITCHING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES;

EID: 84891154322     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.11.001     Document Type: Article

References (48)

1. Anderson I.M., Ferrier I.N., Baldwin R.C., Cowen P.J., Howard L., Lewis G., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. JPsychopharmacol 2008, 22:343-396.
2. Bandelow B., Baldwin D.S., Dolberg O.T., Andersen H.F., Stein D.J. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorderα. JClin Psychiatry 2006, 67:1428-1434.
3. Bauer M., Pfennig A., Severus E., Whybrow P.C., Angst J., Moller H.J., Son behalf of the Task Force on Unipolar Depressive D World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 2013, 14:334-385.
4. Berman R.M., Fava M., Thase M.E., Trivedi M.H., Swanink R., McQuade R.D., et al. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009, 14:197-206.
5. Berman R.M., Marcus R.N., Swanink R., McQuade R.D., Carson W.H., Corey-Lisle P.K., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. JClin Psychiatry 2007, 68:843-853.
6. Chen J., Gao K., Kemp D.E. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011, 24:10-17.
7. Chen S.J., Hsiao Y.L., Shen T.W., Chen S.T. The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial. JClin Psychopharmacol 2012, 32:56-60.
8. Connolly K.R., Thase M.E. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011, 71:43-64.
9. Corrigan P.W., Salzer M.S. The conflict between random assignment and treatment preference: implications for internal validity. Eval Program Plann 2003, 26:109-121.
10. Fava M., Mischoulon D., Iosifescu D., Witte J., Pencina M., Flynn M., et al. Adouble-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 2012, 81:87-97.
11. Fredman S.J., Fava M., Kienke A.S., White C.N., Nierenberg A.A., Rosenbaum J.F. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. JClin Psychiatry 2000, 61:403-408.
12. Guy W. ECDEU assessment manual for psychopharmacology, revised 1976, National Institute of Mental Health, Rockville, MD, DHEW Pub. No. (ADM) 76-338.
13. Han C., Pae C.U. Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorderα. CNS Drugs 2013, 27(Suppl.1):S47-S51.
14. Han C., Wang S.M., Kato M., Lee S.J., Patkar A.A., Masand P.S., et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother 2013, 13:851-870.
15. Han C., Yeh T.L., Kato M., Sato S., Chang C.M., Pae C.U. Management of chronic depressive patients with residual symptoms. CNS Drugs 2013, 27(Suppl.1):S53-S57.
16. Jing Y., Guo Z., Kalsekar I., Forbes R.A., Hebden T., Thase M.E. Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010). Int Clin Psychopharmacol 2013, 28:87-90.
17. Kaptchuk T.J. The double-blind, randomized, placebo-controlled trial: gold standard or golden calfα. JClin Epidemiol 2001, 54:541-549.
18. Kennedy S.H., Lam R.W., Cohen N.L., Ravindran A.V. Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Can J Psychiatry 2001, 46(Suppl.1):38S-58S. Group CDW.
19. Kohler S., Unger T., Hoffmann S., Steinacher B., Fydrich T., Bschor T. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. Pharmacopsychiatry 2013, 46:69-76.
20. Kornbluh R., Papakostas G.I., Petersen T., Neault N.B., Nierenberg A.A., Rosenbaum J.F., et al. Asurvey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull 2001, 35:150-156.
21. Lin C.H., Lin S.H., Jang F.L. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study. JClin Psychopharmacol 2011, 31:563-568.
22. Marcus R.N., McQuade R.D., Carson W.H., Hennicken D., Fava M., Simon J.S., et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. JClin Psychopharmacol 2008, 28:156-165.
23. Mischoulon D., Nierenberg A.A., Kizilbash L., Rosenbaum J.F., Fava M. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry 2000, 45:476-481.
24. Mischoulon D., Witte J., Levy M., Papakostas G.I., Pet L.R., Hsieh W.H., et al. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. JClin Psychiatry 2012, 73:353-357.
25. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166:980-991.
26. Nierenberg A.A., Trivedi M.H., Gaynes B.N., Mitchell J., Davis L.L., Husain M.M., et al. Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder. Aust N Z J Psychiatry 2009, 43:956-967.
27. Pae C.U., Forbes A., Patkar A.A. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011, 25:109-127.
28. Pae C.U., Han C., Jun T.Y. Do we need more than one antidepressant for patients with major depressive disorderα. Expert Rev Neurother 2011, 11:1561-1564.
29. Pae C.U., Jeon H.J., Lee B.C., Seo H.J., Kim S.G., Park E.J., et al. Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study. Int Clin Psychopharmacol 2013, 28:322-329.
30. Pae C.U., Patkar A.A. Clinical issues in use of atypical antipsychotics for depressed patients. CNS Drugs 2013, 27(Suppl.1):39-45.
31. Pae C.U., Patkar A.A., Jun T.Y., Lee C., Masand P.S., Paik I.H. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress Anxiety 2007, 24:522-526.
32. Pae C.U., Wang S.M., Lee S.Y., Lee S.J. Early switch strategy in patients with major depressive disorder. Expert Rev Neurother 2012, 12:1185-1188.
33. Papakostas G.I., Fava M., Thase M.E. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 2008, 63:699-704.
34. Papakostas G.I., Petersen T.J., Green C., Iosifescu D.V., Yeung A.S., Nierenberg A.A., et al. Adescription of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry 2005, 17:161-165.
35. Patkar A.A., Pae C.U. Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder. CNS Drugs 2013, 27(Suppl.1):S29-S37.
36. Patkar A.A., Peindl K., Mago R., Mannelli P., Masand P.S. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim Care Companion J Clin Psychiatry 2006, 8:82-87.
37. Rocha F.L., Fuzikawa C., Riera R., Hara C. Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis. JClin Psychopharmacol 2012, 32:278-281.
38. Ruhe H.G., Huyser J., Swinkels J.A., Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. JClin Psychiatry 2006, 67:1836-1855.
39. Rush A.J. STAR*D: what have we learnedα. Am J Psychiatry 2007, 164:201-204.
40. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011, 168:689-701.
41. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
42. Severus E., Seemuller F., Berger M., Dittmann S., Obermeier M., Pfennig A., et al. Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. BMC Med 2012, 10:67.
43. Simon J.S., Nemeroff C.B. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. JClin Psychiatry 2005, 66:1216-1220.
44. Swift J.K., Callahan J.L. The impact of client treatment preferences on outcome: a meta-analysis. JClin Psychol 2009, 65:368-381.
45. TenHave T.R., Coyne J., Salzer M., Katz I. Research to improve the quality of care for depression: alternatives to the simple randomized clinical trial. Gen Hosp Psychiatry 2003, 25:115-123.
46. Thase M.E. Antidepressant combinations: widely used, but far from empirically validated. Can J Psychiatry 2011, 56:317-323.
47. Winter S.E., Barber J.P. Should treatment for depression be based more on patient preferenceα. Patient Prefer Adherence 2013, 7:1047-1057.
48. Yoshimura R., Kishi T., Hori H., Ikenouchi-Sugita A., Katsuki A., Umene-Nakano W., et al. Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2012, 39:355-357.